company background image
MSB logo

Mesoblast ASX:MSB Stock Report

Last Price

AU$1.03

Market Cap

AU$1.2b

7D

-5.1%

1Y

-12.8%

Updated

23 Jun, 2024

Data

Company Financials +

MSB Stock Overview

Engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.

MSB fundamental analysis
Snowflake Score
Valuation4/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Mesoblast Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Mesoblast
Historical stock prices
Current Share PriceAU$1.03
52 Week HighAU$1.43
52 Week LowAU$0.26
Beta2.4
11 Month Change-12.77%
3 Month Change210.61%
1 Year Change-12.77%
33 Year Change-52.55%
5 Year Change-30.51%
Change since IPO28.13%

Recent News & Updates

Recent updates

Does Mesoblast (ASX:MSB) Have A Healthy Balance Sheet?

Jun 21
Does Mesoblast (ASX:MSB) Have A Healthy Balance Sheet?

Does Mesoblast (ASX:MSB) Have A Healthy Balance Sheet?

Jun 06
Does Mesoblast (ASX:MSB) Have A Healthy Balance Sheet?

Auditors Are Concerned About Mesoblast (ASX:MSB)

Sep 04
Auditors Are Concerned About Mesoblast (ASX:MSB)

Analysts Are More Bearish On Mesoblast Limited (ASX:MSB) Than They Used To Be

Mar 04
Analysts Are More Bearish On Mesoblast Limited (ASX:MSB) Than They Used To Be

Shareholder Returns

MSBAU BiotechsAU Market
7D-5.1%1.7%0.8%
1Y-12.8%5.3%10.3%

Return vs Industry: MSB underperformed the Australian Biotechs industry which returned 5.3% over the past year.

Return vs Market: MSB underperformed the Australian Market which returned 10.3% over the past year.

Price Volatility

Is MSB's price volatile compared to industry and market?
MSB volatility
MSB Average Weekly Movement26.3%
Biotechs Industry Average Movement10.8%
Market Average Movement8.3%
10% most volatile stocks in AU Market16.1%
10% least volatile stocks in AU Market3.2%

Stable Share Price: MSB's share price has been volatile over the past 3 months.

Volatility Over Time: MSB's weekly volatility has increased from 18% to 26% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200483Silviu Itescuwww.mesoblast.com

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.

Mesoblast Limited Fundamentals Summary

How do Mesoblast's earnings and revenue compare to its market cap?
MSB fundamental statistics
Market capAU$1.17b
Earnings (TTM)-AU$109.98m
Revenue (TTM)AU$11.24m

104.1x

P/S Ratio

-10.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MSB income statement (TTM)
RevenueUS$7.47m
Cost of RevenueUS$48.13m
Gross Profit-US$40.66m
Other ExpensesUS$32.40m
Earnings-US$73.06m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.064
Gross Margin-544.50%
Net Profit Margin-978.41%
Debt/Equity Ratio22.8%

How did MSB perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.